Baidu
map

EbioMedicine:复旦学者开辟新冠治疗新策略,或许能将新冠变成“普通感冒”

2022-02-10 “深究科学”公众号 “深究科学”公众号

复旦大学生物医学研究院于文强教授领衔的科研团队最新研究发现新冠致病的罪魁祸首或为HIS基因序列。

复旦大学生物医学研究院于文强教授领衔的科研团队最新研究发现新冠致病的罪魁祸首或为HIS基因序列。

这一全新发现,为新冠病毒感染、患者分类救治和后续有效治疗提供了全新的视

角。近日,国际著名期刊柳叶刀旗下刊物《EbioMedicine》发表了这一重要研究成果。

于文强表示,HIS能激活透明质酸的合成酶,引起透明质酸增加。因此,以透明质酸为靶点抑制其合成,可以成为新冠治疗的新策略。羟甲香豆素是透明质酸合成抑制剂,在中国主要用于治疗胆囊炎,毒副作用极低。

新冠特效药研发如火如荼,但能否应对新冠病毒的不断变异仍需进一步探索,应对新冠变异,我们需要新思路。新冠病毒致病的关键分子是什么?新冠肺炎临床症状的物质基础又是什么?新冠肺炎治疗是否有新的策略呢?SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network》论文的发表为这些问题的解答提供了全新的线索和思路。

疫情初期,于文强团队就已投入到新冠快速检测和致病机制攻关等研究,发现新冠病毒基因组与人类基因组存在5段完全相同的基因序列,团队将其命名为HIS(Human Identical Sequence)。据悉,HIS在159258个新冠病毒基因组广泛存在,且能靶向性地激活人体中肺、血管等非免疫细胞中与炎症相关的基因。

进一步研究发现,新冠病毒HIS可激活人胚肾细胞HEK293T、人胚肺成纤维细胞MRC5和人脐静脉内皮细胞HUVEC中炎症相关基因表达,提示新冠病毒可能激活非免疫细胞表达炎症相关基因,尤其是人体成纤维细胞有可能是新冠病毒感染的重要靶细胞。特别地,HIS能激活新冠病毒受体ACE2,有助于新冠病毒入侵细胞。鉴于此,新冠病毒HIS不仅通过激活炎症相关基因诱发细胞因子风暴,而且可激活病毒受体ACE2表达促进新冠病毒感染。

于文强指出,HIS能够激活透明质酸的合成酶,引起透明质酸增加。透明质酸又名玻尿酸,是常用美容填充剂。作为一种酸性粘多糖,分为大分子和小分子,小分子是重要的炎性介质。“携带HIS基因序列的新冠病毒进入人体后激活炎症相关基因的表达,这可能是引起‘炎症因子风暴’的重要原因。”同时,其团队发现新冠患者血浆中透明质酸会升高,这与淋巴细胞降低和肺部毛玻璃病变等临床症状密切相关。此外,仅用透明质酸处理就能引起小鼠肺部典型CT影像学的毛玻璃病变,进一步证实透明质酸是新冠致病的共同物质基础和治疗新靶点。

鉴于HIS是新冠病毒引起新冠肺炎的关键分子,它能够通过靶向宿主增强子激活炎症相关基因(如HAS2)参与新冠肺炎的发生发展,而透明质酸是新冠肺炎临床症状的物质基础。以透明质酸为靶点抑制其合成,可以成为新冠治疗的新策略。羟甲香豆素是透明质酸合成抑制剂,在中国主要用于胆囊炎的临床治疗。初步临床试验结果显示,羟甲香豆素能显着促进患者体内淋巴细胞恢复,同时改善患者肺部病变。此外,研究人员发现靶向新冠病毒HIS的反义核苷酸能显着抑制HIS对炎症基因及HAS2的激活,提示靶向HIS的小核酸药物也是新冠治疗的可选药物。

该项研究的重大科学意义在于找到了新冠的发病机制,进而明确了要怎么去治疗新冠。幸运的是,研究者找到了羟甲香豆素这样有效的药物。

下一步于文强团队与合作伙伴们将从细胞水平、动物模型和临床试验三个层面入手,深入研究羟甲香豆素对不同新冠变异株的作用及分子机制,以期降低新冠高危人群病死率,将新冠变成“普通感冒”,为全球应对新冠变异和治疗,提供简单易行可推广的中国方案。

原始出处:

Wei Li, et al. SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network. EbioMedicine, 2022.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1924944, encodeId=3a2a192494450, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Wed Aug 31 13:37:28 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774033, encodeId=498a1e74033ab, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Aug 11 01:37:28 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997147, encodeId=6f1d199e1473a, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sat Oct 15 02:37:28 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748808, encodeId=c38a1e48808d8, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Fri Dec 30 18:37:28 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919392, encodeId=1e67191939215, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 24 02:37:28 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859231, encodeId=0bc71859231c1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jul 22 04:37:28 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203072, encodeId=643f12030e2b4, content=有效的治疗方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d3b2210771, createdName=120d521dm50暂无昵称, createdTime=Wed Mar 16 12:03:01 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201850, encodeId=0d5e12018500e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Sat Mar 12 00:17:26 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478470, encodeId=ae8f14e8470b1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538632, encodeId=351b153863293, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1924944, encodeId=3a2a192494450, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Wed Aug 31 13:37:28 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774033, encodeId=498a1e74033ab, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Aug 11 01:37:28 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997147, encodeId=6f1d199e1473a, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sat Oct 15 02:37:28 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748808, encodeId=c38a1e48808d8, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Fri Dec 30 18:37:28 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919392, encodeId=1e67191939215, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 24 02:37:28 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859231, encodeId=0bc71859231c1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jul 22 04:37:28 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203072, encodeId=643f12030e2b4, content=有效的治疗方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d3b2210771, createdName=120d521dm50暂无昵称, createdTime=Wed Mar 16 12:03:01 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201850, encodeId=0d5e12018500e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Sat Mar 12 00:17:26 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478470, encodeId=ae8f14e8470b1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538632, encodeId=351b153863293, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=)]
    2022-08-11 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1924944, encodeId=3a2a192494450, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Wed Aug 31 13:37:28 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774033, encodeId=498a1e74033ab, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Aug 11 01:37:28 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997147, encodeId=6f1d199e1473a, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sat Oct 15 02:37:28 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748808, encodeId=c38a1e48808d8, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Fri Dec 30 18:37:28 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919392, encodeId=1e67191939215, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 24 02:37:28 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859231, encodeId=0bc71859231c1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jul 22 04:37:28 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203072, encodeId=643f12030e2b4, content=有效的治疗方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d3b2210771, createdName=120d521dm50暂无昵称, createdTime=Wed Mar 16 12:03:01 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201850, encodeId=0d5e12018500e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Sat Mar 12 00:17:26 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478470, encodeId=ae8f14e8470b1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538632, encodeId=351b153863293, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=)]
    2022-10-15 linagood
  4. [GetPortalCommentsPageByObjectIdResponse(id=1924944, encodeId=3a2a192494450, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Wed Aug 31 13:37:28 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774033, encodeId=498a1e74033ab, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Aug 11 01:37:28 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997147, encodeId=6f1d199e1473a, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sat Oct 15 02:37:28 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748808, encodeId=c38a1e48808d8, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Fri Dec 30 18:37:28 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919392, encodeId=1e67191939215, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 24 02:37:28 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859231, encodeId=0bc71859231c1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jul 22 04:37:28 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203072, encodeId=643f12030e2b4, content=有效的治疗方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d3b2210771, createdName=120d521dm50暂无昵称, createdTime=Wed Mar 16 12:03:01 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201850, encodeId=0d5e12018500e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Sat Mar 12 00:17:26 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478470, encodeId=ae8f14e8470b1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538632, encodeId=351b153863293, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1924944, encodeId=3a2a192494450, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Wed Aug 31 13:37:28 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774033, encodeId=498a1e74033ab, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Aug 11 01:37:28 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997147, encodeId=6f1d199e1473a, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sat Oct 15 02:37:28 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748808, encodeId=c38a1e48808d8, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Fri Dec 30 18:37:28 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919392, encodeId=1e67191939215, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 24 02:37:28 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859231, encodeId=0bc71859231c1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jul 22 04:37:28 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203072, encodeId=643f12030e2b4, content=有效的治疗方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d3b2210771, createdName=120d521dm50暂无昵称, createdTime=Wed Mar 16 12:03:01 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201850, encodeId=0d5e12018500e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Sat Mar 12 00:17:26 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478470, encodeId=ae8f14e8470b1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538632, encodeId=351b153863293, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=)]
    2022-07-24 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1924944, encodeId=3a2a192494450, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Wed Aug 31 13:37:28 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774033, encodeId=498a1e74033ab, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Aug 11 01:37:28 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997147, encodeId=6f1d199e1473a, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sat Oct 15 02:37:28 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748808, encodeId=c38a1e48808d8, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Fri Dec 30 18:37:28 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919392, encodeId=1e67191939215, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 24 02:37:28 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859231, encodeId=0bc71859231c1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jul 22 04:37:28 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203072, encodeId=643f12030e2b4, content=有效的治疗方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d3b2210771, createdName=120d521dm50暂无昵称, createdTime=Wed Mar 16 12:03:01 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201850, encodeId=0d5e12018500e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Sat Mar 12 00:17:26 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478470, encodeId=ae8f14e8470b1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538632, encodeId=351b153863293, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=)]
    2022-07-22 jeanqiuqiu
  7. [GetPortalCommentsPageByObjectIdResponse(id=1924944, encodeId=3a2a192494450, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Wed Aug 31 13:37:28 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774033, encodeId=498a1e74033ab, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Aug 11 01:37:28 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997147, encodeId=6f1d199e1473a, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sat Oct 15 02:37:28 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748808, encodeId=c38a1e48808d8, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Fri Dec 30 18:37:28 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919392, encodeId=1e67191939215, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 24 02:37:28 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859231, encodeId=0bc71859231c1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jul 22 04:37:28 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203072, encodeId=643f12030e2b4, content=有效的治疗方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d3b2210771, createdName=120d521dm50暂无昵称, createdTime=Wed Mar 16 12:03:01 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201850, encodeId=0d5e12018500e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Sat Mar 12 00:17:26 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478470, encodeId=ae8f14e8470b1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538632, encodeId=351b153863293, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=)]
    2022-03-16 120d521dm50暂无昵称

    有效的治疗方法

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1924944, encodeId=3a2a192494450, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Wed Aug 31 13:37:28 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774033, encodeId=498a1e74033ab, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Aug 11 01:37:28 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997147, encodeId=6f1d199e1473a, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sat Oct 15 02:37:28 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748808, encodeId=c38a1e48808d8, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Fri Dec 30 18:37:28 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919392, encodeId=1e67191939215, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 24 02:37:28 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859231, encodeId=0bc71859231c1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jul 22 04:37:28 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203072, encodeId=643f12030e2b4, content=有效的治疗方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d3b2210771, createdName=120d521dm50暂无昵称, createdTime=Wed Mar 16 12:03:01 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201850, encodeId=0d5e12018500e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Sat Mar 12 00:17:26 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478470, encodeId=ae8f14e8470b1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538632, encodeId=351b153863293, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=)]
    2022-03-12 光明骑士

    学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1924944, encodeId=3a2a192494450, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Wed Aug 31 13:37:28 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774033, encodeId=498a1e74033ab, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Aug 11 01:37:28 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997147, encodeId=6f1d199e1473a, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sat Oct 15 02:37:28 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748808, encodeId=c38a1e48808d8, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Fri Dec 30 18:37:28 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919392, encodeId=1e67191939215, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 24 02:37:28 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859231, encodeId=0bc71859231c1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jul 22 04:37:28 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203072, encodeId=643f12030e2b4, content=有效的治疗方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d3b2210771, createdName=120d521dm50暂无昵称, createdTime=Wed Mar 16 12:03:01 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201850, encodeId=0d5e12018500e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Sat Mar 12 00:17:26 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478470, encodeId=ae8f14e8470b1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538632, encodeId=351b153863293, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1924944, encodeId=3a2a192494450, content=<a href='/topic/show?id=51d359969ac' target=_blank style='color:#2F92EE;'>#普通感冒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59969, encryptionId=51d359969ac, topicName=普通感冒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=754b42, createdName=Luyuxie_9, createdTime=Wed Aug 31 13:37:28 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774033, encodeId=498a1e74033ab, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Aug 11 01:37:28 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997147, encodeId=6f1d199e1473a, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sat Oct 15 02:37:28 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748808, encodeId=c38a1e48808d8, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a79236200456, createdName=xiaoshitou, createdTime=Fri Dec 30 18:37:28 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919392, encodeId=1e67191939215, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 24 02:37:28 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859231, encodeId=0bc71859231c1, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jul 22 04:37:28 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203072, encodeId=643f12030e2b4, content=有效的治疗方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d3b2210771, createdName=120d521dm50暂无昵称, createdTime=Wed Mar 16 12:03:01 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201850, encodeId=0d5e12018500e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Sat Mar 12 00:17:26 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478470, encodeId=ae8f14e8470b1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538632, encodeId=351b153863293, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Thu Feb 10 01:37:28 CST 2022, time=2022-02-10, status=1, ipAttribution=)]
    2022-02-10 saikp

相关资讯

新生儿的“一吻致命”———病毒性脑炎

这种单纯疱疹病毒(HSV1)型病毒也可以引起口唇疱疹,新生儿接触后容易被感染,而新生儿本身免疫功能还未健全,可进一步导致重症感染而危及生命。人们对单纯疱疹病毒可能终身携带,并不一定都表现出临床症状。疱疹病毒脑膜炎症状为:头痛,头晕,感觉迟钝甚至颈项强直等中枢神经功能缺失,但这些则预示著病人已经出现临床症状。

Int J Clin Pract:布洛芬/伪麻黄碱治疗普通感冒 这些影响因素要注意!

普通感冒是最常见的急性呼吸道感染性疾病。2017年2月,发表在《Int J Clin Pract》的一项研究探讨了可影响非处方药布洛芬/伪麻黄碱复方制剂治疗普通感冒症状有效性的因素。请看本期多学科讨论组临床药师各抒己见为您梳理本文看点——目的:本研究的目的为探讨可影响非处方药布洛芬/伪麻黄碱复方制剂治疗普通感冒症状有效性的因素。方法:1770名购买复合制剂治疗自身普通感冒症状的药品消费者的匿名调查

同样嗅觉失灵 新冠感染与普通感冒大有不同

新冠病毒感染者常出现嗅觉失灵。欧洲研究人员最新发现,这种嗅觉失灵和普通感冒引起的嗅觉失灵存在很大差别,相关发现可能有助找到更快捷的新冠感染筛查方法。

涨知识|流行性感冒和普通感冒的区别

流感流行性感冒(简称流感)是流行性感冒病毒引起的急性呼吸系统感染性疾病。病原体为甲、乙、丙三型流行性感冒病毒。临床特征是急起高热、乏力、肌肉酸痛,而呼吸道卡他症状较轻。患者为传染源,主要通过接触及空气飞沫传播。发病有季节性,北方常在冬季,而南方多在冬夏两季,人群普遍易感。老年人及伴有慢性呼吸道疾病、心脏病者易并发肺炎。由于流感病毒尤其是甲型病毒极易变异,往往造成暴发性流行或大流行,一般三年一个流行

儿童流感才不是普通感冒 这类高危人群需积极预防!

据美联邦疾病防治中心表示,去年美国因流感、及其并发症的死亡人数约为8万人,为40年来最高。

Baidu
map
Baidu
map
Baidu
map